Related Experiment Videos
Sentinel node mapping identifies vaccine-draining lymph nodes with tumor-specific immunological activity.
1Department of Surgery and the Massey Cancer Center, Medical College of Virginia at Virginia Commonwealth University, Richmond 23298, USA.
Annals of Surgical Oncology
|February 7, 2002
Summary
Isosulfan blue (IB) mapping identifies crucial lymph nodes for adoptive immunotherapy (AIT). This technique enhances the effectiveness of AIT in treating established mammary carcinomas by pinpointing active immune cells for tumor regression.
Area of Science:
- Immunology
- Cancer Therapy
- Surgical Navigation
Background:
- Adoptive immunotherapy (AIT) using vaccine-draining lymph node (DLN) cells shows promise for treating established mammary carcinomas.
- However, non-DLN remain inactive, limiting treatment efficacy.
- The study investigated if isosulfan blue (IB) mapping could identify DLNs with antitumor activity.
Purpose of the Study:
- To determine if isosulfan blue (IB) mapping can identify immunologically active vaccine-draining lymph nodes (DLNs) for adoptive immunotherapy (AIT).
- To assess the impact of IB on lymphocyte expansion and in vivo anti-tumor efficacy.
Main Methods:
- Isosulfan blue (IB) dye was injected into the vaccination site in mice.
- Blue-stained DLNs were collected, lymphocytes were activated and expanded in culture.
- DLN cell suspensions were adoptively transferred to mice bearing established tumors.
Main Results:
- IB successfully identified both inguinal and axillary lymph nodes.
- Complete tumor regression was observed in mice treated with DLNs identified by IB.
- IB-stained axillary DLNs achieved a 100% cure rate, outperforming blindly collected nodes.
Conclusions:
- Isosulfan blue (IB) effectively identifies immunologically active DLNs for AIT.
- IB does not impede lymphocyte expansion in vitro or anti-tumor activity in vivo.
- IB mapping is crucial for identifying previously inaccessible, yet immunologically active, axillary DLNs.